The replication competent herpes simplex viruses type 1 HSV 1 are promising therapeutic agents for malignant glioma. They can replicate in situ, spread and exhibit oncolytic activity via a direct cytocidal effect. A number of oncolytic HSV 1 viruses have been developed in recent years that have mutations in genes associated with neurovirulence and or viral DNA synthesis to restrict viral replication to transformed cells.
The scheme of oncolytic virus therapy G47 G47 can replicate in situ, spread and exhibit oncolytic activity via a direct cytocidal effect in malignant glioma cells. On the contrary, G47 cannot replicate in normal cells. 
